Erenumab clinical trials
Also written Aimovig and AMG 334.
How each study uses erenumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the erenumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 May 2018 · AIMOVIG · BLA 761077 (FDA, Drugs@FDA)
- European Union
- 26 Jul 2018 · Aimovig · EMEA/H/C/004447 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
52 studies that test it; most in 2019 (15)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 15 |
| 2020 | 9 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 32 · Other 20
Amgen (23) · Novartis Pharmaceuticals (7) · Danish Headache Center (6) · Mayo Clinic (4) · University of Maryland, Baltimore (2) · Indiana University (1) · Charite University, Berlin, Germany (1) · Merle Diamond (1)
Often tested with
Tested in the same studies.
Galcanezumab (3) · Eptinezumab (2) · Ubrogepant (1) · Atogepant (1) · Siltuximab (1) · Calcitonin Gene-Related Peptide (1) · Onabotulinum toxin A (1) · Botulinum toxin type A (1)
Related medicines
As reviewed, each with the page that says it.
- One of CGRP receptor antagonists source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test erenumab.
- Nov 2027Screening Trial for Pain Relief in Schwannomatosis (STARFISH)Phase 2 · Massachusetts General Hospital
Studies
Open first, then newest update. How each study uses erenumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 52
- Screening Trial for Pain Relief in Schwannomatosis (STARFISH)RecruitingPhase 2Massachusetts General HospitalNCT05684692Written as Erenumab-AooeHow we know
- Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)Not yet recruitingPhase 4Stanford UniversityNCT07655440Written as Erenumab 70 mgHow we know
- Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBIRecruitingPhase 2Henry M. Jackson Foundation for the Advancement of Military MedicineNCT05049057Written as Erenumab 140 Mg/mL Subcutaneous SolutionHow we know
- Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With ErenumabRecruitingPhase 4Danish Headache CenterNCT04592952Written as ErenumabHow we know
- Registry for Migraine - Structural and Functional MRI Before and After Erenumab TreatmentRecruitingPhase 4Danish Headache CenterNCT04674020Written as ErenumabHow we know
- Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic MigraineCompletedPhase 3AmgenNCT03832998Written as Erenumab Dose 1How we know
- Efficacy and Safety of Erenumab in Pediatric Participants With Episodic MigraineActive, not recruitingPhase 3AmgenNCT03836040Written as Erenumab Dose 1How we know
- Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic MigraineCompletedPhase 4AmgenNCT04252742Written as ErenumabHow we know
- Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTHCompletedPhase 2Mayo ClinicNCT04098250Written as ErenumabHow we know
- Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine PatientsCompletedPhase 3Novartis PharmaceuticalsNCT03867201Written as ErenumabHow we know
- A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse HeadacheCompletedPhase 4AmgenNCT03971071Written as Erenumab 70 mgHow we know
- Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular DisorderCompletedPhase 2Indiana UniversityNCT04884763Written as Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatmentsHow we know
- Investigational Use of Erenumab for the Treatment of Fibromyalgia PainWithdrawnPhase 3United States Naval Medical Center, PortsmouthNCT06411067Written as ErenumabHow we know
- Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label StudyCompletedPhase 4Novartis PharmaceuticalsNCT04084314Written as ErenumabHow we know
- A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With MigraineCompletedPhase 4AmgenNCT04825678Written as ErenumabHow we know
- Biomarker and Genetic Predictors of Erenumab Treatment ResponseCompletedPhase 4AmgenNCT04265755Written as ErenumabHow we know
- Real World Effectiveness of Eptinezumab in Participants With MigraineTerminatedPhase 4H. Lundbeck A/SNCT05284019Written as ErenumabHow we know
- AMG 334 20160172 Pediatric Migraine PK Study.CompletedPhase 1AmgenNCT03499119Written as AMG 334 Dose 1How we know
- Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)TerminatedPhase 2University of Maryland, BaltimoreNCT05162027Written as Erenumab-Aooe 70 MG in 1 mL Prefilled SyringeHow we know
- Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.TerminatedPhase 2University of Maryland, BaltimoreNCT05142228Written as Erenumab-AooeHow we know
See all 52 studies that test erenumab →
As the comparator · 1 — what is tested is compared with erenumab
What changed recently
From the registry's own updates since Oct 20, 2026.
Results posted1
- Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic MigraineOct 28, 2026NCT03832998
Codes
What other systems call erenumab · ClinicalTrials.gg INT000414
- MeSH (NLM) C000605816erenumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) I5I8VB78VTERENUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2045613Confirmed FDA, Wikidata
- Wikidata Q28209017erenumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169958ErenumabOne source FDA
- DrugBank DB14039One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000605816 | erenumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | I5I8VB78VT | ERENUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2045613 | — | Confirmed FDA, Wikidata |
| Wikidata | Q28209017 | erenumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169958 | Erenumab | One source FDA |
| DrugBank | DB14039 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.